NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387…

NanoViricides’ NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu

In the face of evolving viral threats such as the emerging COVID-19 variant NB1.8.1 ‘Nimbus’ and highly pathogenic Bird Flu strains, NanoViricides, Inc. has positioned its antiviral candidate NV-387 as a critical tool in global pandemic preparedness. The company’s announcement underscores NV-387’s unique mechanism of action, which mimics heparan sulfate structures, a universal viral binding site, thereby minimizing the likelihood of viral resist…

NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu

NanoViricides, Inc. (NYSE American: NNVC) has spotlighted NV-387, its innovative antiviral candidate, as a critical solution to the escalating global health threats posed by emerging COVID-19 variants, such as NB1.8.1 ‘Nimbus’, and evolving strains of Bird Flu. The company’s announcement underscores NV-387’s unique mechanism of action, which mimics heparan sulfate structures, a universal viral binding site, thereby minimizing the likelihood of v…